Evidence map›Paper›PMID 41536287›Full record

ArticleACS pharmacology & translational science2026

Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs.

Rebecca Racz, Laura B Kozell, Amy J Eshleman, Shelley H Bloom, Katherine M Wolfrum, Jennifer L Schmachtenberg, Tracy L Swanson, Jamie Ngai, William E Schutzer, Aaron Janowsky and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rebecca RaczOffice of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Laura B KozellResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Amy J EshlemanResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Shelley H BloomResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Katherine M WolfrumResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Jennifer L SchmachtenbergResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Tracy L SwansonResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Jamie NgaiOffice of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.
William E SchutzerResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Aaron JanowskyResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.
Atheir I AbbasResearch Service, Veterans Affairs Portland Health Care System, Portland, Oregon 97239, United States.ORCID https://orcid.org/0000-0002-7080-3509
Lidiya StavitskayaOffice of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.ORCID https://orcid.org/0000-0002-6307-2314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vesicular monoamine transporter 2 (VMAT2) is an internal membrane protein found predominantly in the central nervous system that plays an integral role in the transport of biogenic monoamines (e.g., dopamine, serotonin, and norepinephrine) into synaptic vesicles for storage within the neuron. While multiple drugs that inhibit VMAT2 have been approved by the US Food and Drug Administration (FDA) for the treatment of hyperkinetic movement disorders, it has been reported that off-target interaction with VMAT2 may lead to neuropsychiatric consequences. In the present study an

Indexed as

approved drugsdopamine uptakeneurologic adverse eventsneurological adverse eventsneurotransmittersvesicular monoamine transporter (VMAT2)

Identifiers

PMID41536287
PMCPMC12797167

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.